Mechanism-based drug safety testing using innovative in vitro liver models: from DILI prediction to idiosyncratic DILI liability assessment
Open Access
- 11 June 2025
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 21 (7) , 769-787
Abstract
Idiosyncratic drug-induced liver injury (iDILI) remains unpredictable. As adverse responses arise in a small fraction of patients, drugs often fail in later drug development stages or post-approval, thereby tremendously increasing costs and putting patients at risk, highlighting the need for accurate early identification of iDILI liabilities. Using articles from the last 5 years (PubMed), iDILI risk factors are described, in vitro liver models and mechanism-based readout strategies are evaluated on their potential to enable iDILI liability assessment. Various in vitro liver models are established for disease modeling and DILI prediction. Drawbacks for each of these seem inevitable, making the evaluation of their application domain and iDILI liability assessment potential crucial. A tiered approach could be considered, whereby compounds are initially screened and flagged using simple fit-for-purpose models for DILI prediction, followed by multicellular liver models that integrate the current knowledge of iDILI onset in combination with mechanistic readouts. Multiplexing models within an integrated mechanism-based testing strategy could improve the safety assessment accuracy. Defined in vitro models should integrate critical hepatocyte intrinsic risk factors as well as adaptive immune system components to refine iDILI liability assessment.Keywords
Funding Information
- Partnership for the Assessment of Risks from Chemicals (101057014)
- TXG-MAP project (GP/EFSA/ED/2022/01)
- European Food Safety Authority
- RISK-HUNT3R project (964537)
- European Union’s Horizon 2020 Research and Innovation Programme
This publication has 135 references indexed in Scilit:
- Human Nonalcoholic Steatohepatitis on a ChipHepatology Communications, 2020
- A Microphysiological System for Studying Nonalcoholic SteatohepatitisHepatology Communications, 2019
- Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injuryArchives of Toxicology, 2018
- Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injuryArchives of Toxicology, 2017
- Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injuryArchives of Toxicology, 2017
- High-content imaging-based BAC-GFP toxicity pathway reporters to assess chemical adversity liabilitiesArchives of Toxicology, 2016
- Immortalized Human Hepatic Cell Lines for In Vitro Testing and Research Purposes2014
- High-content screening of drug-induced mitochondrial impairment in hepatic cells: effects of statinsArchives of Toxicology, 2014
- Human Leukocyte Antigen (HLA)-B*57:01-Restricted Activation of Drug-Specific T cells Provides the Immunological Basis for Flucloxacillin-Induced Liver InjuryHepatology, 2012
- Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacinHepatology, 2004